卖什么
把常规血液和细胞学影像转化为基因组洞察，服务血液学实验室。
商业模式拆解
买家：谁掌握预算？
未核实Lab directors of hematology and cytopathology diagnostic labs.
触发点：什么让他们现在购买？
Molecular testing is costly, slow and complex; fewer than half of US patients get guideline-recommended testing like NGS.
工作流：什么输入变成什么输出？
Integrates with the lab's imaging hardware, analyses whole-slide images of routine smears for genomic biomarkers, and triages samples before conventional NGS/molecular testing.
经济账：省了什么，怎么收费？
未核实Software sold to labs that integrates with their imaging hardware to triage molecular testing; value claim is faster turnaround and less NGS cost; pricing not published.
渠道：怎么接触到客户？
未核实Direct sales to diagnostic laboratories (contact form).
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-05-06 | — | €2.8M | — | news.google.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.